# Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

> **NCT00265837** · PHASE3 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 72 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **BIOLOGICAL:** graft versus host disease prophylaxis/therapy
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** in vitro-treated bone marrow transplantation

## Key facts

- **NCT ID:** NCT00265837
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265837, "Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00265837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*